Tempus AI Launches OneOme Pharmacogenomics Testing Solution, Delivering Advanced Genetic Insights To Optimize Medication Safety, Dosing And Toxicity Risk Assessment
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of its OneOme pharmacogenomics (PGx) testing solution,
Tempus AI released a new test that uses genetics to help doctors pick the right medicine doses for each person and avoid bad reactions. When a company launches a new product, watch if doctors start using it and if it helps the company make more money.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.